Telomir Pharmaceuticals Inc
Company Profile
Business description
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
Contact
100 SE, 2nd Street
Suite 2000, No.1009
MiamiFL33131
USAT: +1 786 396-6723
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
This former ASX tech darling is now 25% undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,291.30 | 23.50 | 0.25% |
| CAC 40 | 8,298.91 | 20.32 | 0.25% |
| DAX 40 | 26,511.08 | 163.63 | 0.62% |
| Dow JONES (US) | 52,231.89 | 157.86 | -0.30% |
| FTSE 100 | 10,788.61 | 37.02 | 0.34% |
| HKSE | 24,315.92 | 241.12 | -0.98% |
| NASDAQ | 25,065.87 | 187.27 | -0.74% |
| Nikkei 225 | 61,248.59 | 789.01 | 1.31% |
| NZX 50 Index | 14,179.86 | 12.45 | 0.09% |
| S&P 500 | 7,520.93 | 29.01 | -0.38% |
| S&P/ASX 200 | 9,153.20 | 24.20 | 0.27% |
| SSE Composite Index | 3,680.64 | 16.92 | 0.46% |